Rigel Pharmaceuticals Inc. is looking to last week's deal with AstraZeneca plc as the springboard from small cap biotech to fully functioning biopharmaceutical company. The deal provides Rigel with enough money to invest in its...

Although big series A rounds have become increasingly commonplace, the recent deal for Albireo AB, expected to reach $40 million, reflects business as usual for Nomura Phase4 Ventures. The London firm has taken an aggressive...

VRTX received a $15 million milestone payment from JNJ's Janssen Pharmaceutica K.K. subsidiary under a deal that gave JNJ an exclusive license to develop and commercialize VX-950 to treat HCV in Europe, South America, the...